Prevalence of *Helicobacter pylori* infection among COVID-19 patients in Baghdad province

Firas Qays Jameel

Bachelor's degree from faculty of pharmacy, Cairo university, Egypt
*Corresponding author: firaskjumai@gmail.com

ABSTRACT

In recent years *Helicobacter pylori* consider as a worldwide public health and a social problem in many countries, The cases of *H.pylori* infection showed a significant increase in our country in last years, some of recent studies highlight on there are correction between *H.pylori* infection and Gastrointestinal Symptoms in COVID-19 patients This study was aimed to Prevalence of *Helicobacter pylori* infection among COVID-19 patients in Baghdad province. This study was conducted on 120 patients with COVID-19 Infection and gastrointestinal symptoms, their age 22 to 65 years, in period extended from September 2021 to June 2022 in Medical AL- Imammian AL- Kadhmain City teaching Hospital; Baghdad teaching Hospital And COVID-19 Isolation center. The stool and blood samples of COVID -19 Infection have been collected, Non-invasive test (SAT and Cag-IgG) were evaluated in all patients, CTK.biotech and Assure® *H. pylori* IgG Rapid tests were used and the result confirmed by PCR .

The result has been showed *H. pylori* were prevalence 76 (63.3%), 73(60.8), 80(66.6 %) samples using SAT, Cag-IgG and PCR respectively. The highest rate of *H. pylori* infection was discovered among COVID-19 patients with the age group 55 – 65 years, with the significant differences between them ($p < 0.05$).the highest prevalence of *H. pylori* infection was founded in O blood.

Keywords: *Helicobacter pylori*, gastrointestinal symptoms, COVID-19.

Introduction

The prevalence of *H. pylori* infections is approximately 30- 50% in developed countries and 70-90% in developing countries (1). According to few studies in Iraq, accurate information about the prevalence of this bacterium is not yet available. However, one study indicated that the prevalence of bacterium was 11.3-71.3% (2). *Helicobacter pylori* (*H. pylori*) represent one of the most prevalent pathogens in humans, which affecting more than half of the population. This bacterium is usually acquired during childhood to persist for many years if remain untreated. (1,2). Infected people usually remain a symptomatic, but, approximately 30% of individuals may develop gastro-duodenal disease with symptoms (3). In COVID -19 patients, the most prevalent GI symptoms include nausea, vomiting, abdominal pain and diarrhea, which can occur in up to 50% of the patients [4] Subsequently, these symptoms can become more severity with existence of H. pylori that play an important role in increase in the expression of ACE2 receptors in the GI tract, and directly linked to the infection progression and promoting immunological dysregulation through its virulent factors (5).As a results, the initial discovery of H. pylori has become a crucial to the diagnosis and selection of the appropriate course of treatment.Due to the presence of *H. pylori*, which is directly linked to

the progression of the infection and promotes immunological dysregulation through its virulent factors these may subsequently become more severe (5). A few studies conducted in Iraq indicate that more investigation is required to ascertain the bacterium `s exact prevalence. According to the most recent research by Majeed *and colleagues* [6], the prevalence of *Helicobacter. Pylori* was 11.3-71.3%. (6).

Materials and Methods
Sample Collection
Totally, 120 patients with COVID-19 Infection and gastrointestinal symptoms, their age 25 to 65 years, in period extended from September 2021 to June 2022 in Medical AL- Imammian AL-Kadhmain City teaching Hospital; Baghdad teaching Hospital And COVID-19 Isolation center. The stool and blood samples of COVID - 19 Infection have been collected, Non-invasive test (SAT and Cag-IgG) were evaluated in all patients, CTK.biotech and Assure® *H. pylori* IgG Rapid tests were used and the result confirmed by PCR .

Blood collection
 In gel and clot activator tube, about 3 ml of venous blood were collected from each patients .each tube was labeled by patients ID stickers with patients name, number, age and date of collection, the tubes were centrifuged and serum aspirated into several Eppendorf tubes (150μ) and stored at -20ºC until be tested [7].

Stool collection
 In a sterile container, about 100-200 mg of stool were collected, if samples were not tested immediately. All stool samples were stored at 2-8 ∘ C or at room temperature up to 37ºC for 10 days. For longer storage, the extracted specimens were frozen at -20ºC [8].

Sample Examination
Stool antigen test (SAT)
This test was done by immune-chromatographic assay using HPAg rapid test for qualitative detection of HPAg in fecal specimen. The procedure was performed according to manufactures instructions [9]. Briefly, stool sample was collected into a disposable container, and shacked vigorously to ensure a homogenous liquid suspension. In case

of watery feces, the plastic dropper was filled with the specimen; while in solid fecal samples, random specimen was collected using the collection stick in 2 -5 different sites .

The stool collection device was hold vertically and the cap was twist off and about two drops (70-85 μl) was dispensed of the solution in to the sample well of the cassette and the solution was not over load. Results were read at 10 minute; if only the C line developed, the result will considered negative and the test indicated no detectable *H. pylori* antigen in the specimen. Positive result appeared when the both C and T lines developed.

Detection of CagA-IgG
This test was done by *H. pylori* rapid test as an immunochromato-graphic assay for qualitative detection of *H. pylori* CagA- IgG Ab in human blood specimen, which constitute an antibody-antigen complexes with immobilized *H. pylori* antigens on the membrane. The bound antibody- antigen complexes can be detected subsequently by antihuman IgG conjugated to colloidal gold.

The test kit is having three bands. The first band is the control line that contains protein A that binds to human IgG and the anti-human IgG colloidal gold conjugate and act as an indicator for proper sample addition. The second band is the CIM line contains antibodies against recombinant current infection marker (CIM) which is indicative of current infection. The third band is the test line that contains an antigen of *H. pylori* [10]. Serum samples were tested and interpreted according to the manufacturer's instructions.

Statistical Analysis
SPSS, Version 27, was used for Statistical analysis, Chi-square and 0.05 alpha-level were used to elevate distinctions between groups.

Results & Discussion
Diagnosis of *Helicobacter Pylori*
Accurate diagnosis of *H.pylori* infection is a crucial part in the effective management of many gastroduodenal diseases. non-invasive diagnostic tests are available for the detection of *H.pylori* and each test has its usefulness and limitations in different clinical situations, Although none can be considered as a single gold standard in clinical practice, several

techniques have been developed to give the more reliable results (8). Each of the methods for confirmation of *H.pylori* infection has a characteristic sensitivity and specificity which may influence an investigation's outcome. Selecting particular methods for the diagnosis depends on access to the methodologies and/or being cost-effective

1.Stool Antigen Test (SAT)

120 stool samples were collected from patients with COVID-19 Infection and gastrointestinal symptoms and tested by ELISA, the result revealed 76 (63.3%), of specimens were positive as shown in Table (1), The sensitivity & specificity was found to be (95.1 %), (86.3 %), respectively.

Table (1): Detection of *H.pylori* by ELISA in stool samples

Type of sample	Positive samples	Negative samples	Total
Stool	76 (63.3%)	44(36.7%)	120(100%)

When comparison current result with other Iraqi results of different studies it was found that, the present result was higher than other Iraqi study done by (7), who used non-invasive techniques including stool antigen test (SAT) to confirm the *H.pylori* infection, The positive results was (67%), with 95% and 91.2% sensitivity and specificity respectively. Also the current result was much higher than that obtained by Al-Mashhadany *et al.* (8) who reported much lower percentage (11.3%) from Kurdistan region, Iraq by using SAT method. The present study was recorded higher percentage than other Arabian study by by (9) from Egypt who stated 64.6% occurrence rate using SAT method Global study as (10). in Indonesia observe that the sensitivity of SAT was 88.8%.

2. Antibody-Based Tests

Due to the small amount of bacteria that colonizes the stomach, Thus, several indirect tests, including antibody based tests such as serology test have been developed to diagnose *H. pylori* infection (11). It was found that, the total number of sera samples (120) were tested by ELISA, there are 73(60.8), of specimens were positive by IgG antibody as shown in Table (2). The sensitivity & specificity was found to be (92.4 %) (84.6 %), respectively.

Table (2): Detection of *H.pylori* by ELISA in Serum samples

Type of sample	Positive samples	Negative samples	Total
Serum	73 (60.8%)	47(39.2%)	120(100%)

The specificity of current result was 60.8% which is less than the serological part of an iraqi study done (11) who found that, the specificity was 84.2%. Another study done by Atkinson and Braden (12) they found that the specificity of serological test was 79-90% which also higher than the current study. Amgalanbaatar *et al.* (13) found that a sensitivity was 82%, their result is being lower than current observed This method has a sensitivity and specificity of 76–84% and 79–90%, respectively according to (14) The ability of this test to detect active infections depends on the patient's age, clinical conditions of infection, the choice of the antigen used for antibody preparation in ELISA kit, and the prevalence of infection (15).

3. Detection of *H.pylori* by16S ribosomal RNA gene

The *16SrRNA* gene was used as housekeeping gene in this study to confirm the present of *H.pylori*, which appeared as band at (470bp), the result found 80(66.6 %) of samples were positive as shown in Figure (1) and Table(3). The sensitivity & specificity was found to be (100%) (95.6 %), respectively.

Table (3): Detection of *H. pylori* by PCR in Saliva samples

Type of sample	Positive samples	Negative samples	Total
Saliva	80 (66.6%)	40(39.2%)	120(100%)

Figure (4-1): Agarose gel (2%) stained with RedSafe dye with 75V electrophoresis for detection of *16S rRNA* gene as a PCR product. Lane A,D,E,F,I,J,KM and O shows PCR product. Lane B,C,Land O shows no PCR product. P: DNA ladder (100 bp step), G : Negative control. (70V for 2hr)

The result revealed here was related to result obtained by (16) who found that 60.5% of the samples were positive for the presence of *H.pylori by* the amplification of the *16S rRNA* gene. This gene is present in all bacteria, at the same time, it comprises nucleotide sequences that are specific to a given bacterial genus (17). Findings from Nigeria based on *16SrRNA*, found only 52.38 % of gastritis samples were PCR positive for *H.pylori* (18). *16S rRNA* gene amplification method was found useful for bacterial identification and phylogeny (19). Several properties of the *16SrRNA* gene make it the "ultimate molecular chronometer", the most

common housekeeping genetic marker, and hence, a useful target for clinical identification and phylogeny(20).

Distribution of Patients According to Age

The age of the patients who enrolled in this study ranged from 18 to 85 year, and they were divided into five age groups. The result of present study clarified that the age group 41-60 had the highest infection (44.7%%) followed by the age group 61-85 represented (31.4%) while the lowest infection (23.8%) found in 18-40 age group as showed in (Table.8) with significant differences (P<0.05).

Table 4: distribution of *H. pylori* infection among COVID-19 Patients based on age.

Age (years)	Total No.	Percentage (%)
25 -35	30	25
40-50	39	32.5
55-65	51	42.5
Total	120	100
X^2	9.65	
Calculated P value	0.008(S)	

It was found that the infection percentage in age (55-65 y) more than other groups and that may be due to that, individuals in this age group have more chance to exposure to infection during their work. These results come in agreement with a number of studies such as El-

Shenawy *et al*.[21] who found that *H.pylori* infection increases with age, and can be found more in the population aged $\geq$ 43 years 71.7% (43/60), on the other hand, 28.3% (17/60) were < 43 years. In Iraqi universities Hussein *et al*. [11] found that *H. pylori* infection was

higher among students aged (24–30) years than those aged 18–20 year and student with age 21–23 year. Previous epidemiologic studies on *H.pylori* have shown a high prevalence (35%–67%) among adults in Saudi Arabia. Furthermore, the rate increases with age and is higher in female than male individuals, Abdoh *et al.* (22).

Distribution of Patients According to Blood Groups

Among the COVID -19 infection patients , the highest H. pylori infection was founded in O blood group (43.7%), followed by A (31.2%), B (13.54%), and AB (11.45%). Figure (2) .

Figure (2): *H. pylori* and Blood groups

This result was similar to other studies that manifesting the higher sensitivity of O blood group to *H. pylori* infection (23).While the present results opposed with some studies which explained that The O blood group did not act as a risk factor for H. pylori infection (24).

The Link between Gastrointestinal Symptoms in COVID-19 and Infection of *Helicobacter. Pylori*

In COVID-19 infection patients, our results suggest that *H. pylori* increases gastrointestinal symptoms by '' over – expression of ACE-2 receptors '' in the GI tract, thereby causing more virus to enter enterocytes and associated with the severity of infection .Globally, there is a few data available to compare our results. In Ankara, the study by (25) revealed that the findings of abdominal pain and diarrhea were strongly correlated with the presence of *H. pylori* in COVID-19 patients and we believe this effect is mediated by ACE-2 receptors. According to a recent study, (26) , there is a correlation between *H. pylori* IgG antibodies and COVID-19, implying that *H. pylori*-infected patients may be more susceptible to COVID-19 infection than other people. Researchers have reported that the virus binds angiotensin – converting enzyme – 2 (ACE-2) receptors to enter the cell. ACE2 was an enzyme found in the cell membrane of different tissue of the body , many research has identified ACE2 in the tissue of the heart , kidney , gallbladder , intestine ,lung and testis Li *et al* ., 2020. This indicates that COVID-19 may involve multiple organs, which may also explain the various extra pulmonary symptoms ,Conversely, an increase in ACE2 expression

may facilitate access in to the host of COVID -19 .Also ACE2 was the main receptor for the virus on the human cell surface and highly expressed in the gastrointestinal tissue which interact with the spike protein (SP) , This mean that the gastrointestinal system can be infected and serve as a COVID-19 replication site.(27) Leading to gastrointestinal symptoms , such as diarrhea , vomiting , abdominal pain . Several recent studies have shown that SARS-Cov-2 needs to bind with ACE2 in order to invade human cells . The gastrointestinal epithelial cells express SARS-CoV-2 entry receptors (Uno, 2020): therefore, the GI tract may be a potential transmission route and target organ of SARS-CoV-2 (28). Diarrhea is the most common GI symptom because SARS-CoV-2 could invade enterocytes. However, a number of patients had simple upper GI symptoms, i.e., nausea/vomiting but without diarrhea. Whether the stomach infection is related to UGIS and the susceptibility factors of the stomach for SARS-CoV-2 remain poorly investigated. As we know, gastric intestinal metaplasia (IM) is characterized by the emergence of intestine-specific cell types, including enterocytes. In China and many other countries, the incidence of gastric IM increase with age , and *H. pylori* infection is an important factor resulting in IM (29). In addition, we found that the stomach with *H. pylori* infection history and IM was enriched with enterocytes, and these cells specifically expressed SARS-CoV-2 entry receptor genes ACE2 and TMPRSS2. The gastric mucosa with IM usually occurs alongside parietal cell loss and then leads to gastric juice PH elevation; thus, the SARS-CoV-2 virus is not inactivated by stomach acid (30) The normal gastric mucosa normally secrete gastric juice, and the PH is usually below 3. SARS-Cov-2 can be inactivated by gastric juice; thereby, it may not be infecting the normal stomach. Therefore, we speculate that the stomach with *H. pylori* infection history and IM may be susceptible to SARS-CoV-2.our conclusion that IM and *H. pylori* infection history may be susceptibility factors of SARS-CoV-2, and the mucosal protective agent may be useful for the blockade of SARS-CoV-2 transmission from the stomach to the intestine.

Conclusion

In the present work the following conclusions, based on the aforementioned results, the findings indicate that *Helicobacter Pylori* infection can be regarded as a contributing influence for progressive the gastrointestinal symptoms in COVID – 19 infection and the infection of *Helicobacter pylori* was discovered among COVID-19 patients among the age group 55 – 65 years, with the significant differences between them ($p < 0.05$).

References

1- Carroll IM; Ahmed N; Beesley SM; Khan AA; Ghousunnissa S; and Morain CA. (2004). Microevolution between paired antral and paired antrum and corpus *H. Pylori* isolates recovered from individual patients. J. Med Microbiol, 53, 669-77.

2- Parente JM; da Silva BB; Palha-Dias MP; Zaterka S; Nishimura NF; and Zeitune JM. (2006). *H. Pylori* infection in children of low and high socioeconomic status in northeastern Brazil. Am. Trop. Med. Hyg., 75(3), 509-12.

3- Kayali S, Manfredi M, Gaiani F, Bianchi L, Bizzarri B, Leandro G, Di Mario F, De' Angelis GL.(2018).*Helicobacter pylori*, transmission routes and recurrence of infection: state of the art. Acta Biomed. Dec 17; 89 (8-S):72-76. Doi: 10.23750/abm.v89i8-S.7947.

4- Kopel J, Perisetti A, Gajendran M, et al. (2020). Clinical insights into the gastrointestinal manifestations of COVID-19. Dig Dis Sci; 65:1932–9.

5- Balamtekin N, Artuk C, Arslan M, Gülşen M. (2021). The effect of helicobacter pylori on the presentation and clinical course of coronavirus disease 2019 infection. J Pediatr Gastroenterol Nutr. 72(4):511-3.

6- Majeed PD, Khoshnaw KJ. (2020). Seroprevalence of *Helicobacter pylori* infection among patients with gastroduodenal disorders in Erbil city. Diyala J Med. 18(1):91–101.

7- Chow, T.P. (2001). Assure™ Helicobacter pylori rapid test for the accurate detection of Helicobacter pylori

infection. NUS-ICMR-JSPS International Symposium on Helicobacter and Viral Hepatitis, p. 87.

8- Pelerito, A., Oleastro, M., Lopes, A. I., Ramalho, P., Cabral, J., & Monteiro, L. (2006). Evaluation of rapid test Assure® *Helicobacter pylori* for diagnosis of *H. pylori* in pediatric population. *Journal of microbiological methods*, *66*(2), 331-335.

9- Hussein R.A.; Al-Ouqaili M.T. and Majeed Y.H. (2021). Detection of *Helicobacter Pylori* infection by invasive and non-invasive techniques in patients with gastrointestinal diseases from Iraq: A validation study. *PLoS ONE*, 16(8): e0256393.

10- Al-Mashhadany, D. A. and S. M. Mayass. (2018). Prevalence of *Helicobacter pylori* in Human in Dhamar governorate/Yemen. J. Med. Pharm. Sci. Issue. 1(2): 1-18.

11- Galal YS, Ghobrial CM, Labib JR, Abou-Zekri ME. (2019). Helicobacter pylori among asymptomatic Egyptian Children: Prevalence, risk factors, and effect on growth. J Egypt Public Health Assoc. 94(1):1-8.

12- Miftahussurur, M. and Y. Yamaoka. 2016. Diagnostic Methods of *Helicobacter pylori* infection for epidemiological studies: Critical importance of indirect test validation. Biomed Res. Int. 24: 1-14.

13- Sokpon M.; Salihoun M.; Lahlou L. *et al.* (2016). Predictors of *Helicobacter pylori* (Hp) infection in chronic gastritis: about a Moroccan study. *J Afr Hépatol Gastroentérol*. 10(4), 203–207.

14- Odigie AO, Adewole AJ, Eknwe AA. (2020). Prevalence and factors associated with Helicobacter pylori infection among treatment naïve dyspeptic adults in University of Benin City, Nigeria. African Journal of Clinical and Experimental Microbiology. 21(2), 97-105.

15- Lawson–Ananissoh L.M.; Bouglouga O.; Bagny A. *et al.* (2015). Epidemiological profile of peptic ulcers at the Lomé campus hospital and university center (Togo). *J Afr Hépatol Gastroentérol*, 9(3), 99–103.

16- Baj J, Forma A, Sitarz M, Portincasa P, Garruti G, Krasowska D, et al. (2020). Helicobacter pylori virulence factors-mechanisms of bacterial pathogenicity in the gastric microenvironment. Cells. 10(1):27.

17- Al-Mashhadany DA. (2020).Epidemiology of *Helicobacter pylori* among human at Erbil governorate/Kurdistan region /Iraq.Researchgate.net Vol.9, Issue 11,435-447.

18- M.T. Al-Mossawei, W. H. Rzooqi and S. Abdulrazzaq. 2016. Detection of Helicobacter pylori IgG and IgM antibodies in Iraqi dyspeptic patients. J. Biotechnol. Res. Center. 10(1): 5-9.

19- Al-Windi, A., Hussain, A.H. and Salih, N. (2013). Seroprevalence of anti-*Helicobacter pylori* antibodies in population of Sulaimani governorate/Kurdistan Region/Iraq. Journal of Zankoy Sulaimani- Part A (JZS-A).15(3):175-185.

20- Hanafi M and Mohamed A M. (2013). Helicobacter pylori infection: Seroprevalence and predictors among healthy individuals in Al Madinah, Saudi Arabia. Journal of the Egyptian Public Health Association 88(1), 40-45.

21- Shu X, Ping M, Yin G, Jiang M. (2017). Investigation of Helicobacter pylori infection among symptomatic children in Hangzhou from 2007 to 2014: a retrospective study with 12,796 cases. Peer J 5, e2937.

22- Abdel Rahim NR, Benson J, Grocke K, Vather D, Zimmerman J, and Moody T. (2017).Prevalence of Helicobacter pylori infection in newly arrived refugees attending the Migrant Health Service, South Australia. Wiley Online Library. Helicobacter 22(2), e12360.

23- Sasidharan S, Ghayethry B, Ravichandran M, Latha YL. (2012). Prevalence of *Helicobacter pylori* among patients referred for endoscopy: Gender and ethnic differences in Kedah, Malaysia.

Asian Pacific Journal of Tropical Disease 2(1), 55-59.

24- A. T. B. Abadi, (2018). Diagnosis of *Helicobacter pylori* using invasive and noninvasive approaches. Journal of pathogens. Hindawi.com.

25- El-Shenawy A.; Diab M.; Shemis M.; El-Ghannam M.; Salem D.; Abdelnasser M. and Saber M. (2017). Detection of *Helicobacter pylori vacA, cagA* and *iceA1* virulence genes associated with gastric diseases in Egyptian patients. *Egyptian Journal of Medical Human Genetics*, 18(4), 365-371.

26- Abdoh Q.; Kharraz L.; Ayoub K. *et al.* (2018). *Helicobacter pylori* resistance to antibiotics at the An-Najah National University Hospital: a cross-sectional study. *Lancet*, 391(2), 32-6.

27- Hedayati, M. A., & Salavati, S. (2021). Transcriptional profile of *Helicobacter pylori* virulence genes in patients with gastritis and gastric cancer. *Canadian Journal of Infectious Diseases and Medical Microbiology.*

28- Phattharaphon W.; Chariya C.; Banchob S.; Wises N. and Kiatichai F.(2018). Detection and genotyping of *Helicobacter pylori* in saliva versus stool samples from asymptomatic individuals in Northeastern Thailand reveals intra-host tissue-specific *H.pylori* subtypes. *BMC Microbiology*, 18, 10.

29- Idris A.B.; Hassan H.G.; Ali M.A.S.; Eltaher S.M.; Idris L.B.; Altayb H.N. and Hassan M.A. (2020). Molecular phylogenetic analysis of 16S rRNA sequences identified two lineages of *helicobacter pylori* strains detected from different regions in Sudan suggestive of differential evolution. *International Journal of Microbiology*.

30- Mun X, Ping M, Yin G, Jiang M. (2017). Investigation of Helicobacter pylori infection among symptomatic children in Hangzhou from 2007 to 2014: a retrospective study with 12,796 cases. Peer J 5, e2937.